Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-10-16
2007-10-16
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S141100, C424S135100, C424S138100, C424S139100, C530S388100
Reexamination Certificate
active
10996651
ABSTRACT:
The present invention provides a method for reducing the severity of, or treatment of, plasma cell disorders. The method comprises the step of administering to an individual afflicted with a plasma cell disorder, a composition comprising an antibody directed to the extracellular portion of NOTCH or to JAG2.
REFERENCES:
patent: 6083904 (2000-07-01), Artavanis-Tsakonas
patent: 6291210 (2001-09-01), Sakano et al.
patent: 6689744 (2004-02-01), Gao et al.
patent: 6716974 (2004-04-01), Maciag et al.
patent: 2001/0048930 (2001-12-01), Lamb et al.
patent: 2003/0185829 (2003-10-01), Koller et al.
patent: WO 2004/076682 (2004-09-01), None
De Vos et al., Blood, 2001, vol. 98(3), pp. 771-780.
Gaiger, et al.; Identification of Genes Associated with Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Using the Myeloma Microarray; European Journal of Cancer, Pergamon Press; Nov. 21, 2002, vol. 38, Paragraph 344; XP-002383846; p. S103.
Luo, et al.; Isolation and Functional Analysis of a cDNA for HumanJagged2, a Gene Encoding a Ligand for the Notch1 Receptor; Molecular and Cellular Biology, American Society for Microbiology; Washington, US; Oct. 1997; vol. 17, No. 10; XP-000938415; pp. 6057-6067.
Felli, et al.; Expression Pattern of Notch1, 2 and 3 and Jagged1 and 2 in Lymphoid and Stromal Thymus Components; Distinct Ligand—Receptor Interactions in Intrathymic T Cell Development; International Immunology, vol. 11, No. 77; XP-002384016; pp. 1017-1025, Jul. 1999.
Almeida, et al.; Immunophenotypic and DNA Content Characteristics of Plasma Cells in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance; Pathologie et Biologie, L'Expansion Scientifique Francaise, Paris, FR; Feb. 1999, vol. 47, No. 2; XP-009067443; pp. 119-127.
Houde, et al.; Overexpression of the NOTCH Ligand JAG2 in Malignant Plasma Cells From Multiple Myeloma Patients and Cell Lines; Blood, Dec. 1, 2004, vol. 104, No. 12; XP-002380593; pp. 3697-3704.
Gray, et al.; Human Ligands of the Notch Receptor; American Journal of Pathology; Mar. 1999, vol. 154, No. 3; XP-000960906; pp. 785-794.
Health Research , Inc.
Hodgson & Russ LLP
O'Hara Eileen B.
Xie Xiaozhen
LandOfFree
Use of NOTCH pathway interfering agents for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of NOTCH pathway interfering agents for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of NOTCH pathway interfering agents for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3903125